HOME >> MEDICINE >> NEWS
LA BioMed medical/research briefs March 2005

Researchers Use Breast Imaging System to Detect Cancers Missed by Mammography

Iraj Khalkhali, MD, a principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and a resident physician in the Department of Radiology/Diagnostic Radiology at Harbor-UCLA Medical Center, is part of an international group of researchers studying the use of a breast imaging camera, which appears to detect breast cancers missed by standard mammography.

Approximately 25 to 40 percent of women have dense breast tissue, which decreases the chance that a cancer will be visible on their mammograms. With molecular breast imaging, the visibility of the tumor is not influenced by the density of the surrounding tissue. This technique is well suited to find cancers in women whose mammograms may not be very accurate. Experts have long recognized that screening for breast cancer with mammograms may not be sufficient in some groups of women, particularly women at increased risk for breast cancer, many of whom also have dense breast tissue.

Researchers in Italy, Pennsylvania and the Mayo Clinic have detected previously unknown cancers in patients who had dense breasts and in whom both clinical examinations and mammography reported normal results. "We believe our results show that the routine clinical use of high-resolution, dedicated breast cameras can be a powerful diagnostic tool for early breast cancer identification," Dr. Khalkhali said.

The breast imaging camera used in the study is provided by Gamma Medica, Inc. of Northridge, California. For more information on how to participate in this clinical trial in the Los Angeles area, contact breaststudy@gammamedica.com or call 1-877-788-3908 x 104. For members of the media who wish to talk to Dr. Khalkhali, please contact Dave Feuerherd at df@issuesmanagement.com. To o
'"/>

Contact: David Feuerherd
df@issuesmangement.com
310-215-0234
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
1-Mar-2005


Page: 1 2 3

Related medicine news :

1. LA BioMed medical/research briefs January 2005
2. LA BioMed Medical/Research briefs January 2005
3. LA BioMed Medical/Research Briefs December 2004
4. LA BioMed research briefs
5. BioMed Central -- freedom of information for the science community
6. REI medical/research briefs
7. News briefs from the journal CHEST, March 2005
8. News briefs from the journal CHEST, February 2005
9. News briefs from the journal Chest, January 2005
10. News briefs from the Journal CHEST, December 2004
11. News briefs from the Journal CHEST, November 2004

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: BioMed medical research briefs March

(Date:5/20/2013)... CosmosID, a leading data mining solutions company for health ... results on analysis of labeling claims for the composition ... The Food and Drug Administration (FDA) and CosmosID conducted ... four of which have been reported at the American ... was to compare the identity of species and strains ...
(Date:5/20/2013)... Sporturf, an international manufacturer and builder of synthetic ... Midwest with the opening of the company’s third regional ... is under the leadership of President Craig Shonk, and ... , “This strategic move opens up a market ... Shonk. “Bringing an ISO manufacturer and a Midwest-based ASBA ...
(Date:5/20/2013)... Online education provides the convenience, flexibility and cost-saving ... According to the American Heart Association, 27% of ... to eLearning due to changing economic conditions. The ... budgets, but it is also proven to enhance ... higher retention of content is probable, given the ...
(Date:5/20/2013)... as a consequence of diabetic foot ulcer that does ... this situation are very limited. In his doctoral thesis ... Department of Medical Biochemistry and Biophysics at Ume University ... may completely change the lives of millions of patients. ... chronic wounds that largely impair the quality of life ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 BenefitMall, ... of employee benefit, payroll products and services and ... both are selected as finalists for the 2013 American ... Company of the Year category, and CompuPay is a ... finalist will ultimately be a Gold, Silver or Bronze ...
Breaking Medicine News(10 mins):Health News:CosmosID unveils new tool for faster, specific and accurate testing of probiotics products 2Health News:Sporturf Expands into the Midwestern U.S. 2Health News:Swank HealthCare Announces New Offering of Additional American Heart Association’s Accredited Online Courses 2Health News:Discovery of a novel medicine for the treatment of chronic wounds 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 3
(Date:5/20/2013)... ALISO VIEJO , Kalifornien, 20. Mai ... heute bekannt, dass das Unternehmen die CE-Kennzeichnung ... Implantate zur Embolisation von Aneurysmen erhalten hat. ... in Europa bereits mit der kontrollierten Einführung ... Profil bietet die SL-Produktfamilie auch ein verbessertes ...
(Date:5/20/2013)... Enrollment of patients with Type 2 diabetes ... trial of product candidate NewMet ™, a delayed-release ... 2 diabetes. Elcelyx expects to complete enrollment of 240 ... of the trial,s primary endpoint of change in fasting ... read-out for long-term glucose lowering and weight benefits is ...
(Date:5/20/2013)... 20, 2013  AbbVie (NYSE: ABBV ... 3 clinical study called SONAR (Study Of Diabetic ... the investigational compound atrasentan - when added to standard ... patients with stage 2 to 4 chronic kidney ... a large, multinational, double-blind, placebo-controlled clinical study that ...
Breaking Medicine Technology:Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
Cached News: